KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Short term Debt (2016 - 2025)

Historic Short term Debt for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $3.8 billion.

  • AbbVie's Short term Debt fell 6984.88% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year decrease of 6984.88%. This contributed to the annual value of $6.8 billion for FY2024, which is 538.17% down from last year.
  • According to the latest figures from Q3 2025, AbbVie's Short term Debt is $3.8 billion, which was down 6984.88% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, AbbVie's Short term Debt ranged from a high of $12.6 billion in Q2 2024 and a low of $2.0 billion during Q2 2025
  • In the last 5 years, AbbVie's Short term Debt had a median value of $7.2 billion in 2023 and averaged $7.7 billion.
  • Per our database at Business Quant, AbbVie's Short term Debt soared by 26403.57% in 2024 and then crashed by 8410.93% in 2025.
  • Quarter analysis of 5 years shows AbbVie's Short term Debt stood at $12.5 billion in 2021, then tumbled by 66.87% to $4.1 billion in 2022, then soared by 73.91% to $7.2 billion in 2023, then decreased by 5.38% to $6.8 billion in 2024, then crashed by 44.3% to $3.8 billion in 2025.
  • Its Short term Debt stands at $3.8 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $3.8 billion for Q1 2025.